SavedAdd your journal

Journals / Ege Klinikleri Tıp Dergisi / 2021 / Cilt: 59 - Sayı: 1

Clinical Outcomes of Patients Presenting with Pulmonary Embolism

Pulmoner Emboli ile Başvuran Hastaların Klinik Sonuçları

Eyüp AVCI
Nuri KÖSE
Tarık YILDIRIM
Pages
1–7
Publication Date
2022-10-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Thrombolytic treatment can be administered safely and efficiently in selected cases with pulmonary embolism, and provides fast and significant clinical improvement in these patients.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Acute pulmonary embolism is closely associated with severe morbidity and mortality.
📊
Key Findings & Data:Materials and Methods: The clinical and demographic characteristics, concomitant diseases, predisposing factors, and treatment outcomes of 26 patients whom were diagnosed with pulmonary embolism and treated with 2 hours of infusion of 100 mg alteplase at diagnosis in our clinic between 2011 and 2015 were retrospectively evaluated.
💡
Conclusion & Impact:Thrombolytic treatment can be administered safely and efficiently in selected cases with pulmonary embolism, and provides fast and significant clinical improvement in these patients.
🔬Design:Research Article
📍Scope:2011 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: Acute pulmonary embolism is closely associated with severe morbidity and mortality. Treatment guidelines recommend taking rapid action and application of thrombolytic treatment in selected cases. The aim of this study is to evaluate the outcomes of thrombolytic treatment among our cases in accordance with the guidelines. Materials and Methods: The clinical and demographic characteristics, concomitant diseases, predisposing factors, and treatment outcomes of 26 patients whom were diagnosed with pulmonary embolism and treated with 2 hours of infusion of 100 mg alteplase at diagnosis in our clinic between 2011 and 2015 were retrospectively evaluated. Results: Data from 26 patients (M/F: 8/18) with a mean age of 65.817.1 years (30-86 years) and mean symptom duration of 58.972.4 hours (2- 288 hours) were included in the analyses. Most frequent symptom and concomitant disease were shortness of breath (96.2%) and systemic hypertension (57.7%), respectively. Deep venous thrombosis was the predominant risk factor (69.2%). Pulmonary embolism was most frequently found in bilateral pulmonary arteries (42.3%). Mean pulmonary arterial systolic pressures before and after treatment were 54.55.9 (45- 70) mmHg and 26.22.1 (22-30) mmHg, respectively. Two patients had minor hemorrhage after thrombolytic application, and all patient survived 1 year after treatment. Conclusion: Most important factors for prognosis in pulmonary embolism are fast and accurate diagnosis, and appropriate treatment. Thrombolytic treatment can be administered safely and efficiently in selected cases with pulmonary embolism, and provides fast and significant clinical improvement in these patients.

Özet

Amaç: Akut pulmoner emboli yüksek mortalite ve morbidite ile ilişkilidir. Tedavi klavuzları seçilmiş hastalarda trombolitik tedavi düşünülmesini ve tedavide hızlı davranılmasını önerir. Bu çalışmanın amacı pulmoner emboli hastalarında uyguladığımız trombolitik tedavilerin sonuçlarını kılavuzlar ışığında değerlendirmektir. Gereç ve Yöntem: Kliniğimizde 2011 ile 2015 tarihleri arasında, pulmoner emboli tanısı konulan ve alteplaz 100mg dozunda 2 saat intravenöz infüzyon ile trombolitik tedavi uygulanan 26 hastanın klinik ve demografik bulguları, eşlik eden hastalıkları, predispozan faktörleri ve tedavi sonuçları değerlendirildi. Bulgular: Analize dahil edilen 26 hastanın (E/K:8/18) ortalama yaşı of 65.817.1 yıl (30-86 yıl) ve ortalama semptom süresi 58.972.4 saat (2- 288 saat) idi. En sık görülen semptom nefes darlığı (% 96,2) ve en sık eşlik eden hastalık sistemik arteriyal hipertansiyon (% 57,7) idi. Derin ven trombozu dominant risk faktörü idi (% 69.2). Pulmoner emboli en sık bilateral pulmoner arterlerde saptandı (% 42,3). Pulmoner arter sistolik basınçları tedavi öncesi ortalama 54.55.9 (45-70) mmHg ve tedavi sonrası ortalama 26.22.1 (22-30) mmHg idi. İki hastada trombolitik tedavi sonrası minör kanama saptandı ve tüm hastalar tedaviden 1 yıl sonra sağ kaldı. Sonuç: Pulmoner embolide prognozu etkileyen en önemli faktörler doğru ve hızlı tanı konulması ve uygun tedavinin uygulanmasıdır. Pulmoner embolide seçilmiş olgularda trombolitik tedavi yüksek başarı oranı ile uygulanabilir ve hastaların klinik durumunda erken ve belirgin düzelme sağlar.

🔖

Cite This Article

AVCI, E., KÖSE, N., YILDIRIM, T. (2022). Clinical Outcomes of Patients Presenting with Pulmonary Embolism. Ege Klinikleri Tıp Dergisi, Cilt: 59 - Sayı: 1, 1–7. https://ajindex.com/articles/495624

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Klok FA, van Kralingen KW, van Dijk AP,et al. Quality of life in long-term survivors of acute pulmonary embolism. Chest 2010;138(6):1432–40
  2. Fanikos J, Piazza G, Zayaruzny M, Goldhaber SZ. Long-term complications of medical patients with hospital-acquired venous thromboembolism. Thromb Haemost 2009;102(4):688–93. 3.Bĕlohlávek J, Dytrych V, Linhart A. Pulmonary embolism, part I: Epidemiology, risk factors and risk stratification, pathophysiology, clinical presentation, diagnosis and nonthrombotic pulmonary embolism.Exp Clin Cardiol. 2013 Spring;18(2):129-38
  3. Arcasoy SM, Kreit JW. Thrombolytic therapy of pulmonary embolism: a comprehensive review of current evidence. Chest. 1999;115(6):1695-707
  4. Konstantinides SV, Torbicki A, Agnelli G,et al. 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism: Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC).Eur Heart J. 2014;35(43):3033-69. 6.Kucher N, Goldhaber SZ. Management of massive pulmonary embolism.Circulation. 2005;112(2):e28-32
  5. Kasper W, Konstantinides S, Geibel A,et al. Management strategies and determinants of outcome in acute major pulmonary embolism: results of a multicenter registry.J Am Coll Cardiol. 1997;30(5):1165-71
  6. Fengler BT, Brady WJ. Fibrinolytic therapy in pulmonary embolism: an evidencebased treatment algorithm.Am J Emerg Med. 2009;27(1):84-95
  7. Konstantinides S, Geibel A, Olschewski M,et al. Association between thrombolytic treatment and the prognosis of hemodynamically stable patients with major pulmonary embolism: results of a multicenter registry. Circulation. 1997;96(3):882-8
  8. Goldhaber SZ, Haire WD, Feldstein ML,et al. Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion. Lancet. 1993;341(8844):507-11
  9. Meneveau N, Ming LP, Séronde MF,et al. In-hospital and long-term outcome after sub-massive and massive pulmonary embolism submitted to thrombolytic therapy. Eur Heart J. 2003;24(15):1447-54
  10. Konstantinides SV, Vicaut E, Danays T,et al. Impact of Thrombolytic Therapy on the Long-Term Outcome of Intermediate-Risk Pulmonary Embolism. J Am Coll Cardiol. 2017;69(12):1536-44
  11. Torbiki A, Galie N, Covezzoli A, Rossi E, Goldhaber S. Right heart thrombi in pulmonary embolism: results from the International Cooperative Pulmonary Embolism Registry. J Am Coll Cardiol 2003; 41(12): 2245-51.